5-Fluorocytosine increases the toxicity of Wnt-targeting replicating adenoviruses that express cytosine deaminase as a late gene

Gene Therapy

Volumn 11, Issue 2, 2004, Pages 142-151

  Fuerer, C ^a   Iggo, R ^a  

^a SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

Author keywords

Alternative splicing; Colon cancer; Cytosine deaminase; Internal ribosome entry site; Suicide gene

Indexed keywords

ADENOVIRUS VECTOR; CYTARABINE; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; ONCOLYTIC VIRUS; ONCOPROTEIN; PRODRUG; PROTO ONCOGENE PROTEIN INT 1; PROTO-ONCOGENE PROTEIN INT-1; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA; WNT PROTEIN;

ADENOVIRUS; ALTERNATIVE RNA SPLICING; CANCER CELL CULTURE; CELL STRAIN HT29; COLON CANCER; COLON TUMOR; CONTROLLED STUDY; DRUG CYTOTOXICITY; EXON; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; GENETICS; HUMAN; HUMAN CELL; INTERNAL RIBOSOME ENTRY SITE; METABOLISM; METHODOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SACCHAROMYCES CEREVISIAE; TUMOR CELL LINE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS REPLICATION; WESTERN BLOTTING;

ADENOVIRIDAE; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYTOSINE DEAMINASE; FLUCYTOSINE; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HT29 CELLS; HUMANS; PRODRUGS; PROTO-ONCOGENE PROTEINS; TRANSCRIPTION, GENETIC; VIRUS REPLICATION; WNT PROTEINS; ZEBRAFISH PROTEINS;

ADENOVIRIDAE; DNA VIRUSES; SACCHAROMYCES; SACCHAROMYCES CEREVISIAE;

EID: 0742271997     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302148     Document Type: Review

References (54)

1. Bischoff JR et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376.
2. Heise C et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000; 6: 1134-1139.
3. Hallenbeck PL et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999; 10: 1721-1733.
4. Rodriguez R et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997; 57: 2559-2563.
5. Johnson L et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 2002; 1: 325-337.
6. Brunori M, Malerba M, Kashiwazaki H, Iggo R. Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway. J Virol 2001; 75: 2857-2865.
7. Fuerer C, Iggo R. Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway. Gene Therapy 2002; 9: 270-281.
8. Hernandez-Alcoceba R, Pihalja M, Qian D, Clarke MF. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum Gene Ther 2002; 13: 1737-1750.
9. Wickham TJ. Ligand-directed targeting of genes to the site of disease. Nat Med 2003; 9: 135-139.
10. Greco O, Dachs GU. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol 2001; 187: 22-36.
11. Kirn D, Niculescu-Duvaz I, Hallden G, Springer CJ. The emerging fields of suicide gene therapy and virotherapy. Trends Mol Med 2002; 8: S68-73.
12. Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 2000; 18: 299-313.
13. Freytag SO et al. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 1998; 9: 1323-1333.
14. Rogulski KR et al. Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum Gene Ther 2000; 11: 67-76.
15. Bett AJ, Prevec L, Graham FL. Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 1993; 67: 5911-5921.
16. Sauthoff H et al. Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein. Hum Gene Ther 2002; 13: 1859-1871.
17. Harada JN, Berk AJ. p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J Virol 1999; 73: 5333-5344.
18. Rothmann T et al. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 1998; 72: 9470-9478.
19. Edwards SJ et al. Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14 (ARF) tumor suppressor genes. J Virol 2002; 76: 12483-12490.
20. Freytag SO et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 2002; 62: 4968-4976.
21. Hawkins LK, Hermiston T. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the E3B region. Gene Therapy 2001; 8: 1142-1148.
22. Hawkins LK, Hermiston TW. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the ADP region. Gene Therapy 2001; 8: 1132-1141.
23. Hawkins LK et al. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp 19 K region. Gene Therapy 2001; 8: 1123-1131.
24. Bauzon M et al. Multigene expression from a replicating adenovirus using native viral promoters. Mol Ther 2003; 7: 526-534.
25. Yu DC et al. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 1999; 59: 4200-4203.
26. Suzuki K, Alemany R, Yamamoto M, Curiel DT. The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin Cancer Res 2002; 8: 3348-3359.
27. Ginsberg HS, Prince GA. The molecular basis of adenovirus pathogenesis. Infect Agents Dis 1994; 3: 1-8.
28. Hamstra DA et al. Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Hum Gene Ther 1999; 10: 1993-2003.
29. Nyati MK et al. High and selective expression of yeast cytosine deaminase under a carcinoembryonic antigen promoter-enhancer. Cancer Res 2002; 62: 2337-2342.
30. Rosin-Arbesfeld R, Cliffe A, Brabletz T, Bienz M. Nuclear export of the APC tumour suppressor controls beta-catenin function in transcription. EMBO J 2003; 22: 1101-1113.
31. van de Wetering M et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002; 111: 241-250.
32. Bunz F et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282: 1497-1501.
33. Wong ET, Ngoi SM, Lee CG. Improved co-expression of multiple genes in vectors containing internal ribosome entry sites (IRESes) from human genes. Gene Therapy 2002; 9: 337-344.
34. Muhlemann O, Yue BG, Petersen-Mahrt S, Akusjarvi G. A novel type of splicing enhancer regulating adenovirus pre-mRNA splicing. Mol Cell Biol 2000; 20: 2317-2325.
35. Brough DE et al. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol 1996; 70: 6497-6501.
36. Broker TR. Nucleotide sequences, transcription and translation analyses and restriction enzyme cleavage maps of group C adenoviruses. In: Tooze J (ed). DNA Tumour Viruses. Cold Spring Harbor: New York, 1981, pp 994-995.
37. Bernt KM et al. Enzyme-activated prodrug therapy enhances tumor-specific replication of adenovirus vectors. Cancer Res 2002; 62: 6089-6098.
38. Heise C et al. Onyx-015, an E1b gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3: 639-645.
39. Reid T et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002; 62: 6070-6079.
40. Khuri FR et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885.
41. Chung-Faye GA et al. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Therapy 2001; 8: 1547-1554.
42. Ciccolini J et al. Combination of thymidine phosphorylase gene transfer and deoxyinosine treatment greatly enhances 5-fluorouracil antitumor activity in vitro and in vivo. Mol Cancer Ther 2001; 1: 133-139.
43. Wierdl M et al. Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase. Cancer Res 2001; 61: 5078-5082.
44. Lipinski KS et al. High-level, beta-catenin/TCF-dependent transgene expression in secondary colorectal cancer tissue. Mol Ther 2001; 4: 365-371.
45. Hermiston TW, Kuhn I. Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther 2002; 9: 1022-1035.
46. Post DE, Khuri FR, Simons JW, Van Meir EG. Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum Gene Ther 2003; 14: 933-946.
47. Kruyt FA, Curiel DT. Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum Gene Ther 2002; 13: 485-495.
48. Ring CJ. Cytolytic viruses as potential anti-cancer agents. J Gen Virol 2002; 83: 491-502.
49. Hawkins LK, Lemoine NR, Kirn D. Oncolytic biotherapy: a novel therapeutic plafform. Lancet Oncol 2002; 3: 17-26.
50. Bell JC, Lichty B, Stojdl D. Getting oncolytic virus therapies off the ground. Cancer Cell 2003; 4: 7-11.
51. Sikorski RS, Hieter P. A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics 1989; 122: 19-27.
52. Gagnebin J et al. A photosensitising adenovirus for photodynamic therapy. Gene Therapy 1999; 6: 1742-1750.
53. Reich NC, Sarnow P, Duprey E, Levine AJ. Monoclonal antibodies which recognize native and denatured forms of the adenovirus DNA-binding protein. Virology 1983; 128: 480-484.
54. Marton MJ, Baim SB, Ornelles DA, Shenk T. The adenovirus E4 17-kilodalton protein complexes with the cellular transcription factor E2F, altering its DNA-binding properties and stimulating E1A-independent accumulation of E2 mRNA. J Virol 1990; 64: 2345-2359.